Business
Sisram Medical Delivers Strong Third-Quarter 2025 Performance with Robust Momentum Across Key Markets and Core Businesses
Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, today announced its business update for the third quarter of 2025, highlighting solid revenue growth and accelerated momentum across core product segments and key markets.
About this update from Sisram Medical Ltd.
[{"type":"text","content":"HONG KONG, Oct. 28, 2025 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, today announced its business update for the third quarter of 2025, highlighting solid revenue growth and accelerated momentum across core product segments and key markets.","length":499,"tagName":"p"},{"type":"text","content":"In the third quarter of 2025, the Company achieved double-digit revenue growth compared to the same period last year, driven by strong double-digit year-on-year growth in new orders, primarily supported by robust demand across key markets in China, South Korea, and Thailand.","length":275,"tagName":"p"},{"type":"text","content":"The EBD business maintained strong growth, with sustained market momentum for Alma Harmony, the award-winning multiplatform launched globally in March 2025, which recorded a significant volume of new orders during the quarter. Building on this success, the Soprano family of laser devices delivered impressive performance in the APAC region, highlighted by the latest launch of Soprano in China that secured substantial new orders.","length":431,"tagName":"p"},{"type":"text","content":"The injectables business continued its strategic expansion, serving as a key growth engine for Sisram. Notably, DAXXIFY received approval from the National Medical Products Administration, becoming the first botulinum toxin type A product approved in Mainland China that features a proprietary Peptide Exchange Technology (PXT) and a stabilized-peptide formulation. With dedicated efforts to accelerate commercial preparations, the launch of DAXXIFY in Mainland China remains on track, injecting renewed momentum into the Company's injectables segment and overall ecosystem.","length":578,"tagName":"p"},{"type":"text","content":"Globally, Sisram deepened its footprint in strategic markets, advancing its "glocalization" strategy through a series of focused initiatives. The newly established direct sales office in Thailand continued to deliver strong injectable sales, demonstrating effective localization. In the U.S., the Company officially launched Universkin by Alma, the worl...